Kenvue Inc. (KVUE) Covered Calls

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue, formerly the Consumer Healthcare division of Johnson & Johnson. The company manages a portfolio of iconic, science-backed brands including Tylenol, Neutrogena, Listerine, and Aveeno. It operates across three main segments: Self Care, Skin Health and Beauty, and Essential Health. Kenvue focuses on delivering everyday healthcare solutions through global retail, e-commerce, and professional channels.

You can sell covered calls on Kenvue Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for KVUE (prices last updated Thu 4:16 PM ET):

Kenvue Inc. (KVUE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
18.55 +0.01 18.54 18.55 64.7M 24 36
Covered Calls For Kenvue Inc. (KVUE)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 18.5 0.42 18.13 2.0% 81.1%
Mar 20 19 0.46 18.09 2.5% 24.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Kenvue Inc. is a global leader in consumer health, having completed its full separation from Johnson & Johnson in 2023. The company owns some of the most recognized household brands in the world, positioned at the intersection of healthcare and consumer goods. Its business model is built on high-volume, repeat-purchase products that address everyday needs in pain management, skincare, and hygiene. In late 2025, the company entered into a definitive agreement to be acquired by Kimberly-Clark, a move aimed at combining Kenvue’s brand strength with a larger global distribution and supply chain network.

Core Business and Products

The company’s diverse portfolio is organized into three strategic segments:

  1. Self Care: This is the largest segment, featuring over-the-counter (OTC) medicines such as Tylenol (pain relief), Zyrtec and Benadryl (allergy), and Nicorette (smoking cessation).
  2. Skin Health and Beauty: Includes science-driven skincare brands like Neutrogena and Aveeno, as well as specialized products for sun protection and hair care.
  3. Essential Health: Comprises everyday personal care products, led by Listerine (oral care), Band-Aid (wound care), and Johnson’s (baby care).

Competitive Landscape

Kenvue competes with large-cap diversified consumer staples and specialized health firms. In the OTC and self-care space, its primary rivals include Haleon and the consumer health divisions of Pfizer and Bayer. In skin health and beauty, it faces stiff competition from Estee Lauder, e.l.f. Beauty, and Procter & Gamble. For essential health products, it competes globally with Colgate-Palmolive and Church & Dwight. Kenvue differentiates itself by leveraging the clinical heritage and "healthcare professional recommended" status it inherited from its time as part of a pharmaceutical giant.

Strategic Outlook and Innovation

The strategic outlook for 2026 is dominated by the pending merger with Kimberly-Clark. This "hybrid" operating model is designed to accelerate growth by plugging Kenvue’s brands into a more efficient global supply chain while maintaining local market speed. Innovation is currently focused on "premiumization"—launching specialized, higher-margin versions of core products, such as dermatologist-tested skincare treatments and long-acting allergy relief. The company is also aggressively expanding its digital footprint to capture more sales through direct-to-consumer and e-commerce platforms. By focusing on productivity gains and portfolio optimization (including the potential divestiture of lower-performing sub-brands), the group aims to stabilize its margins and provide a defensive, dividend-paying profile for its investors.